Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYELO-WASP
- Development stage
- Preclinical
- Lead developer
- BIMINI Biotech
- Modality
- Small Molecules
01
Overview
MYELO-WASP is a preclinical-stage research program being developed by BIMINI Biotech, in collaboration with the Institute of Oncology Research (Switzerland) and Navegador Biosciences (Portugal). Supported by a Eureka Eurostars grant awarded in April 2026, the program focuses on the development of first-in-class small-molecule modulators targeting the Wiskott-Aldrich Syndrome Protein (WASp) for the treatment of myeloid and lymphoid leukemias, with a primary focus on Acute Myeloid Leukemia (AML). WASp is a key regulator of actin cytoskeleton dynamics and immune cell signaling, and its modulation represents a novel therapeutic approach to induce apoptosis or inhibit proliferation in leukemic cells.
02
Targets
WAS (Wiskott-Aldrich syndrome protein)
Beyond the preview
Go deeper on MYELO-WASP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYELO-WASP.